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ABSTRACT
Mutations in the tumor suppressor gene NF2 lead to Neurofibromatosis type 
2 (NF2), a tumor predisposition syndrome characterized by the development of 
schwannomas, including bilateral vestibular schwannomas with complete penetrance. 
Recent work has implicated the importance of COX-2 in schwannoma growth. Using 
a genetically engineered murine model of NF2, we demonstrate that selective 
inhibition of COX-2 with celecoxib fails to prevent the spontaneous development 
of schwannomas or sensorineural hearing loss in vivo, despite elevated expression 
levels of COX-2 in Nf2-deficient tumor tissue. These results suggest that COX-2 is 
nonessential to schwannomagenesis and that the proposed tumor suppressive effects 
of NSAIDs on schwannomas may occur through COX-2 independent mechanisms.
INTRODUCTION
Neurofibromatosis type 2 (NF2) is an inherited 
tumor predisposition syndrome affecting 1 in 25,000 
people, most of whom are germline heterozygous for the 
NF2 tumor suppressor gene [1]. The hallmark of NF2 is the 
development of bilateral vestibular schwannomas (VS), 
which lead to sensorineural hearing loss, tinnitus, and 
vestibular dysfunction as well as brainstem compression, 
hydrocephalus, and death with sufficiently large tumors. 
There are currently no approved chemotherapeutic 
agents for the treatment of schwannomas, owing in 
part to an incomplete understanding of the biochemical 
derangements that occur as a result of NF2-deficiency.
Although the molecular pathogenesis of VS is an 
area of active investigation, several lines of evidence 
support the hypothesis that COX-2 overexpression 
contributes to schwannoma growth. COX-2 is an inducible 
enzyme involved in the biosynthesis of prostanoids from 
arachidonic acid. Prostaglandin E2 (PGE2) is the best-
understood effector of COX-2 in the setting of malignancy 
and has been implicated both as having direct effects on 
tumor cells as well as affecting immune surveillance within 
the tumor microenvironment [2]. Immunohistochemical 
staining of spontaneous and NF2-related VS suggested 
a correlation between tumor proliferation and COX-2 
expression [3]. A retrospective case series found that low 
dose aspirin inversely correlated with the propensity for 
sporadic VS growth on serial magnetic resonance imaging. 
This finding suggests that there may be a link between 
aspirin’s COX-2 or NFκB inhibitory functions and 
schwannoma growth [4]. Importantly, compared to normal 
Schwann cells, primary cultured human VS cells were 
shown to have increased COX-2 expression, increased 
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secretion of PGE2, and reduced proliferation when treated 
with a COX-2 inhibitor [5].
COX-2 also intersects with a second biochemical 
pathway of recent interest in NF2 pathogenesis. The 
mammalian Hippo pathway has been a source of great 
interest in the development of NF2-deficient schwannomas. 
Guerrant and colleagues recently found that COX-2 is 
transcriptionally up regulated by YAP, a Hippo pathway 
effector that is transcriptionally activated in the setting of 
NF2- deficiency [6]. Further, that same group demonstrated 
that the COX-2 inhibitor celecoxib suppressed tumor 
expansion in an orthotopic model of tumorigenesis [6]. 
Given that recent data, we questioned whether COX-2 
inhibition could be used as a chemopreventative strategy 
in NF2 mediated schwannoma formation, especially in 
light of the success of inhibition of COX-2 in other cancer 
predisposition syndromes [7]. In addition to its value as 
a treatment modality, effective chemoprevention would 
provide a rationale for diagnosing individuals at known 
genetic risk for NF2 prior to tumor initiation.
While no animal model system can serve as 
a perfect analog to human disease, there are unique 
advantages to the use of genetically engineered mouse 
(GEM) models of cancer. Compared to cell-line derived 
xenograft (CDX) models, GEM cancer models provide a 
much closer surrogate for human disease by allowing the 
spontaneous development of tumors from defined primary 
tumorigenic cells within their native stroma and immune 
microenvironment [8]. The Nf2flox/flox;Periostin-Cre (Nf2f/f; 
PostnCre) mouse model developed in our laboratory 
eliminates the production of Merlin, the protein product 
of Nf2, in the Schwann cell lineage. Mice expressing Cre 
recombinase develop spontaneous schwannomas of the 
dorsal root ganglia (DRG) and cranial nerves with 100% 
penetrance [9]. Using this established model of NF2, we 
tested the hypothesis that chemopreventative COX-2 
inhibition attenuates spontaneous schwannomagenesis or 
sensorineural hearing loss (SNHL).
RESULTS
COX-2 is overexpressed in Nf2-deficient mouse 
model of NF2
To assess whether COX-2 was overexpressed in 
the setting of Nf2-deficient tumor-forming tissue, we 
examined protein levels of COX-2 in the trigeminal 
ganglia of 6-month-old mice. At this anatomic site, mice 
with a conditional-knockout of Nf2 (Nf2f/f;PostnCre+) 
exhibit Schwann cell hyperplasia or frank schwannoma 
formation by 6 months of age. Relative to strain 
equivalent Nf2-sufficient mice (Nf2f/f;PostnCre-), COX-
2 was markedly increased in the trigeminal ganglia of 
Nf2f/f;PostnCre+ mice (Figure 1A). As expected, levels 
of the Nf2 protein product Merlin were diminished in the 
Nf2f/f;PostnCre+ tissue relative to Nf2-sufficient controls. 
The faint Merlin immunostaining present in the Nf2f/f; 
PostnCre+ samples likely represents Merlin expression in 
non-Schwann cell lineages within the ganglia.
We then examined the expression of PTGS2, the 
gene encoding COX-2, in RNA extracted from trigeminal 
ganglia tissue. PTGS2 expression was increased 3.9-fold 
in Nf2f/f;PostnCre+ mice (95% CI 1.97–5.80) compared to 
Nf2f/f;PostnCre- controls (P=.004, Figure 1B). This fold-
increase in expression is comparable to that observed by 
Dilwali et al. in primary cultured human VS cells [5]. To 
better approximate the PTGS2 fold-increase, one tissue 
sample from an Nf2f/f;PostnCre+ mouse was removed as 
it met the criteria for a high outlier (PTGS2 fold-increase 
of 16.0). Together, these results suggest that COX-2 is 
aberrantly expressed in Nf2-deficient, tumor-forming 
tissue, a finding consistent with prior published work [5].
Figure 1: COX-2 is increased in Nf2-deficient mouse model of neurofibromatosis type 2. (A) Western blot analysis of COX-
2 and Merlin in whole tissue lysate of tumor-forming trigeminal ganglia tissue of 6-month old Nf2f/f;PostnCre- or Nf2f/f;PostnCre+ mice. 
(B) Relative PTGS2 gene expression in trigeminal ganglia tissue of 6-8 month old Nf2f/f;PostnCre- or Nf2f/f;PostnCre+ mice by qPCR. (** 
P=.004).
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Chemopreventative celecoxib treatment of Nf2-
deficient mice
To test the hypothesis that pharmacologic COX-
2 inhibition prevents or slows schwannoma growth, we 
performed a chemopreventative trial of celecoxib in 
Nf2f/f;PostnCre+ mice beginning at 3-5 weeks of age, 
before the initiation of Schwann cell hyperplasia or frank 
schwannoma formation. Celecoxib was administered 
through an ad libitum drug-containing diet until the mice 
reached six months of age. Celecoxib’s half-life has 
been reported to be as low as two hours in mice [10]. In 
addition to being safer than gavage feeding drug multiple 
times per day for several months, administration of 
celecoxib through an ad libitum diet made animals more 
likely to achieve relatively constant levels of celecoxib. 
Once a celecoxib diet was formulated, pharmacokinetic 
evaluation in the plasma and relevant peripheral nervous 
system tissue was performed. We performed HPLC-MS/
MS on plasma and DRG samples of Nf2f/f;PostnCre- 
mice that had been fed celecoxib (N=4) or vehicle 
diets (N=3) for one week. Substantial plasma celecoxib 
levels were achieved in all treated mice (Figure 2A; 
mean 5361 ng/mL plasma; range 2883 to 8230 ng/mL). 
These plasma values, which likely represent steady-
state celecoxib levels in our animals, are on the order 
of maximum concentrations achieved with high-dose 
celecoxib treatment in humans [11]. Similar plasma 
concentrations were achieved in a previous study using 
a GEM cancer model that responded to an ad libitum 
celecoxib diet [12]. We also confirmed that celecoxib 
effectively accumulated in the DRG, our therapeutic 
target (Figure 2B; mean 46672 ng/g tissue; range 24390 
to 76086 ng/g). For mice consuming vehicle diet, no 
celecoxib was detected in plasma or DRG samples.
To ensure our celecoxib-containing diet effectively 
inhibited murine COX-2 in vivo using our dosing strategy, 
mice were fed either the celecoxib-containing or control 
diet for five days and were then injected with 100ng 
lipopolysaccharide (LPS) intraperitoneally to induce 
COX-2 expression. LPS has previously been demonstrated 
to strongly induce COX-2 protein levels and downregulate 
COX-1 in astrocytes [13]. Because levels of COX-2 
are among the highest in brain tissue, the right cerebral 
hemisphere was harvested two hours after injection. Mice 
fed the celecoxib infused diet had a significant reduction 
in COX-2 activity in nervous tissue following induction 
and activation of COX-2 (Figure 2C). This demonstrates 
that the tissue concentrations of celecoxib achievable via 
free feeding are sufficient for significant biochemical 
suppression of COX-2 in our murine model. Taken 
together, these experiments indicate that treatment with 
ad libitum celecoxib diet effectively inhibits COX-2 and 
results in drug concentrations generally exceeding those 
achieved in humans.
Celecoxib does not prevent schwannomagenesis 
in Nf2-deficient mice
Animals began celecoxib treatment at 3-5 weeks of 
age and were treated to the age of six months. Celecoxib 
treatment was generally well tolerated and mice exhibited 
normal growth compared to those on vehicle diet 
(Figure 2D). Three of twelve celecoxib mice and one of 
thirteen vehicle mice died prior to six months of age, a 
difference in survival that was not statistically significant 
(P=.30, survival curves not shown), suggesting that 
chemopreventative celecoxib therapy does not improve 
survival in our model.
Nf2f/f;PostnCre+ mice spontaneously develop 
schwannomas between 5-8 months of age [9]. The 
endpoint of six months was chosen because this is a time 
point at which a delay in schwannoma growth would 
most likely be detected as a difference in tumor volume 
and number. By six months, both celecoxib and vehicle 
treated Nf2f/f;PostnCre+ mice had gross enlargements 
of DRG compared to Nf2f/f;PostnCre- mice (Figure 3A). 
DRG volume was significantly increased in both celecoxib 
and vehicle treated mice relative to Nf2-sufficient controls 
(adjusted P<.001 in both cases). No difference in tumor 
volume was present between celecoxib and vehicle groups 
(adjusted P=.97).
To determine whether the rate of DRG enlargement 
differed between groups, a threshold for pathologically 
increased DRG size was determined. Any DRG greater 
than the 95th percentile of Nf2f/f;PostnCre- was considered 
to be enlarged. No significant difference in the rate of 
DRG enlargement was present between celecoxib and 
vehicle groups (69% and 55% respectively; P=.33).
DRG of celecoxib-treated mice had histologic 
features consistent with schwannoma and were 
indistinguishable from DRG of vehicle-treated controls 
(Figure 3B). DRG architecture was disrupted by Schwann 
cell proliferation to varying degrees within a single animal. 
Taken together, these data suggest that chemopreventative 
celecoxib does not delay spontaneous schwannoma 
formation or growth in vivo.
Celecoxib does not prevent SNHL in Nf2-
deficient mice
Nf2f/f;PostnCre+ mice develop spontaneous SNHL 
which can be detected by changes in ABR threshold as 
previously described [9]. ABR testing was conducted at 
six months of age prior to sacrificing mice. No differences 
were present between thresholds of celecoxib and vehicle 
groups (adjusted P=.72). Thresholds of both vehicle and 
celecoxib-treated Nf2f/f;PostnCre+ mice were significantly 
higher than those of an age-matched group of Nf2f/f; 
PostnCre- mice (adjusted P=.04 and.01 respectively), 
suggesting that hearing loss was present in this study’s 
treatment and control groups. We conclude that celecoxib 
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treatment did not prevent SNHL in our murine model of 
NF2.
DISCUSSION
Our findings fail to establish the efficacy of COX-2 
inhibition as a strategy for the prevention of spontaneous 
tumorigenesis or SNHL in NF2. They support a different 
conclusion than the evidence on this question recently 
published by Guerrant et al., who demonstrated that 
celecoxib inhibits tumor growing in vivo [6]. There are 
differences in design between the two studies. Rather than 
treating existing tumors we sought to determine whether 
we could prevent tumor initiation. Tumor development 
in the Nf2f/f;PostnCre model is spontaneously initiated 
by loss of Nf2 in the Schwann cell lineage, and occurs 
over a period of months [9]. In contrast, tumors formed 
by Guerrant et al. were caused by implantation of the 
SC4 cell line in immunodeficient mice. SC4 cells are 
a rapidly growing, immortalized Nf2-deficient murine 
Schwann cell line. These cells have a doubling time 
between 24 and 48 hours and form tumors over a period 
of days [6]. As others have noted, the biologic relevance 
of CDX models can be diminished by processes related 
to 2D cell culture, including the immortalization of cells 
and selection that occurs over the course of several cell 
passages [8]. In our hands, other immortalized NF2- 
deficient lines such as HEI-193 have hyperproliferative 
phenotypes that are unchanged by Merlin re-expression. 
For this reason, therapeutic responses in such cell lines 
may represent responses of acquired oncogenic drivers 
not present in human disease. Additionally, the use of 
immunocompetent GEM models better approximates the 
tumor microenvironment, a detail of particular importance 
in the study of anti-inflammatory agents that may target 
microenvironmental cells [8].
Several other studies using GEM models of cancer 
have demonstrated therapeutic responses to celecoxib at 
lower or comparable doses than those used in our study 
[12, 14, 15]. We demonstrated that our celecoxib treatment 
achieved considerable plasma levels, effectively reached 
tumor-forming tissue, and effectively decreased COX-
2 activity. Our mice were treated for several months 
throughout the period of spontaneous tumorigenesis. 
Although failing to demonstrate its therapeutic relevance, 
it is important to note that our mouse model recapitulated 
the aberrant COX-2 expression seen in Dilwali et al’s 
study comparing primary cultured human VS cells and 
Figure 2: Chemopreventative celecoxib treatment of Nf2-deficient mice. HPLC-MS/MS analysis of celecoxib levels in (A) 
plasma and (B) DRG tissue between treated and untreated mice. (*P <.05) (C) Mice were fed vehicle or celecoxib infused chow for 5 days 
followed by an IP injection of 100ng of LPS for induction of COX-2. Mice were sacrificed 2 hours post injection. Y axis measures COX-2 
activity in units/mL of tissue lysate (P= 0.0379, unpaired t-test). (D) Mouse body weights of treated and untreated Nf2f/f;PostnCre+ mice.
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Figure 3: Celecoxib fails to prevent schwannomagenesis or SNHL in Nf2-deficient mice. (A) DRG enlargement – 
Representative images of gross DRG enlargement between a Nf2f/f;PostnCre- mouse (left), vehicle and celecoxib-treated Nf2f/f;PostnCre+ 
mice (center and right) are shown (scale bar = 5 mm). Below, DRG volume is shown for the same groups of mice (ns = not significant; P 
>.05). (B) DRG histology – Schwannomas at later and earlier stages of development are shown for both vehicle and celecoxib-treated mice. 
(C) ABR – Thresholds are shown per ear for Nf2f/f;PostnCre-, vehicle and celecoxib-treated Nf2f/f;PostnCre+ mice.
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normal human Schwann cells [5]. The use of this mouse 
model for in vivo validation of biochemical derangements 
identified in primary cultured human VS cells may 
represent an effective strategy for finding translationally 
relevant targets for the treatment of VS.
Work of multiple groups suggests that NSAIDs, 
particularly aspirin, may have therapeutic potential in 
VS [4, 5, 16]. While our findings do not preclude this 
possibility, they do suggest that a response to NSAIDs 
would occur through COX-2 independent mechanisms. 
Aspirin and its metabolite salicylate are also inhibitors of 
the NFκB pathway, which is also activated in VS [17–20]. 
This inhibition occurs at much lower doses than does 
aspirin’s inhibition of COX-2, suggesting the potential that 
NFκB inhibition may be aspirin’s more therapeutically 
relevant effect [21]. There are also other NSAIDs, 
such as diclofenac, which have shown promise in other 
cancers but remain untested in VS [22, 23]. Further study 
using effective cellular and animal models is needed to 
determine whether other molecular targets of NSAIDs are 
effective in the treatment of VS.
MATERIALS AND METHODS
Animals and celecoxib administration
The Indiana University Institutional Animal Care 
and Use Committees approved the animal protocol 
(#10940). Nf2flox/flox;Periostin-Cre mice have been 
previously described [9]. Mice were fed a diet formulated 
to deliver 300 mg/kg/day of celecoxib or an otherwise 
identical vehicle diet (ResearchDiets). Mouse weights 
were recorded every two weeks. Mice were sacrificed 
at 6 months of age and four DRG tumors at consistent 
anatomic locations were measured per mouse as 
previously described [9].
Protein extraction and western blot
Trigeminal ganglia were dissected from 6-month-
old mice and washed thoroughly in PBS. Protein was 
isolated in cell lysis buffer with protease and phosphatase 
inhibitors. Protein concentrations were measured using 
a bicinchoninic acid assay (Thermo Scientific) and 
normalized. Protein samples were resolved with SDS-
polyacrylamide gel electrophoresis and transferred onto 
polyvinylidene difluoride membranes. COX-2 antibody 
was purchased from Santa Cruz Technologies and 
antibodies for Merlin and GAPDH were purchased from 
Cell Signaling Technologies.
Reverse transcription-quantitative polymerase 
chain reaction
RNA was extracted from trigeminal ganglia 
of 6-8 month old mice using Trizol Reagent (Life 
Technologies) per the manufacturer’s instructions. RNA 
concentration was determined using Nanodrop (Thermo 
Scientific) and converted to cDNA using a QuantiTect 
reverse transcription kit (Qiagen). Quantitative PCR was 
performed using a SYBR green kit (Life Technologies), 
probes for PTGS2 and GAPDH, and an Applied 
Biosystems 7500 System.
High performance liquid chromatography and 
mass spectrometry
High performance liquid chromatography (HPLC) 
and Mass Spectrometry (MS) were performed by the 
IU Simon Cancer Center’s Clinical Pharmacology 
Analytical Core. Samples were acidified and extracted 
in hexane:ethyl acetate (50:50, v/v). After solvent 
evaporation, mobile phase (acetonitrile:5mM ammonium 
acetate; 70:30, v/v) was mixed with residual sample 
and injected into an Agilent 1290 HPLC system with an 
Eskigent Autosampler. Mass spectrometry was performed 
using an ABSciex 5500 Q-TRAP.
COX-2 activity ELISA
8-month-old Nf2f/f;PostnCre- mice were separated 
into two groups of 5 mice and fed either celecoxib or 
vehicle diet for 5 days. On day 5, the mice were injected 
intraperitoneally with 100ng of tissue culture grade 
Escherichia coli O111:B4 derived LPS in 100ul of sterile 
PBS. Mice were sacrificed 2 hours later. The left cerebral 
hemisphere was harvested from each mouse. Tissues were 
processed and samples were run as described following 
the factory protocol using the Cayman Chemical COX 
Activity Assay Kit (760151).
Auditory brain stem response
Prior to harvest, mice were anesthetized with 100 
mg/kg ketamine and 10 mg/kg xylazine by intraperitoneal 
injection. ABR signals were recorded from each ear using 
a Tucker Davis Technologies (TDT) MF1 speaker and 
subcutaneous needle electrodes connected to a TDT RZ6 
Multi I/O processor. Clicks were presented at 21/s with 
512 repetitions, sweeping from 30 to 90 dB-SPL in 10 dB 
intervals. Signals were high and low pass filtered (3 Hz-3 
kHz) and averaged in TDT BioSigRZ. Thresholds were 
defined as the lowest SPL at which more than one peak 
was observed and reproducible.
Statistical analysis
qPCR and mouse weights were compared using 
unpaired t tests. For DRG volume and ABR threshold 
data, one-way ANOVA was used and Tukey’s posttest was 
performed to generate adjusted P values. Chi-square test 
was used to test differences in rate of DRG enlargement. 
Survival between groups was compared using a log-rank 
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test. Grubbs test for statistical outliers was performed for 
all data sets. P<.05 was considered statistically significant 
for all tests.
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